Mumbai: Mid-cap pharma major Ajanta Pharma Limited has delivered consistent growth for the full financial year 2026, with its net profits rising 10% to ₹1,056 crore from ₹ 920 crore last year. The company has also seen its revenues surpass the ₹5,000 crore mark with its revenue increasing 13% from last year.
The branded generics major has seen consistent performance across the board, with its US generics vertical witnessing a 49% growth in sales while its Africa business also seeing a 9% sales growth. The management has decided to reward its investors by declaring a final dividend of ₹28 per equity share for the financial year.
Despite challenges with raw material and active pharmaceutical ingredient (API) pricing challenges, Ajanta Pharma has maintained its robust EBITDA margins, which reached 26.5% for the year.
“The year reflects strong well-rounded performance across all areas of business, reinforcing the strength of our strategy and execution. One of the most defining characteristics of Ajanta Pharma’s business model is its diversification—across geographies, therapies, and customer segments. This structural resilience was once again on full display in FY 2026. In years when one market may face external headwinds, other steps forward. This is not coincidence; it is by design.
As we look to FY 2027 and beyond, we do so with conviction. The investments of the past years in our field force, new therapies, new geographies, product pipeline, and people are entering their productive phase. Our Branded Generics businesses in both India and emerging markets are well positioned for strong growth. Our US business will continue to scale responsibly.
We remain committed to the principles that have guided Ajanta Pharma through every phase of its evolution: quality without compromise, growth with margin discipline, and stakeholder value creation with integrity,” the company said in a press release.
Ajanta Pharma remains one of investors’ favorite pharma picks, as it has consistently offered generous dividend payouts. The company is net debt-free, funding its own Research and Development (R&D) through internal accruals. It has, so far, avoided high-risk, debt-fuelled international mega acquisitions, while maintaining its Return on Capital Employed at a strong 28%.
